Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor α

Cancer Research

Volumn 64, Issue 11, 2004, Pages 3849-3854

  Cheung, Connie ^a   Akiyama, Taro E ^a   Ward, Jerrold M ^b   Nicol, Christopher J ^a   Feigenbaum, Lionel ^c   Vinson, Charles ^a   Gonzalez, Frank J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; ACYL COENZYME A OXIDASE; BROXURIDINE; CYTOCHROME P450 4A; FATTY ACID BINDING PROTEIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIRINIXIC ACID; VERY LONG CHAIN FATTY ACID;

ANIMAL CELL; ARTICLE; CANCER SUSCEPTIBILITY; CELL CYCLE; CELL PROLIFERATION; DRUG POTENCY; FATTY ACID METABOLISM; GENE CONTROL; GENE INDUCTION; HEPATOMEGALY; HUMAN; LIPID METABOLISM; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER TUMOR; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PEROXISOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; RISK ASSESSMENT; SPECIES DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; WILD TYPE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CARCINOGENS; CELL DIVISION; DNA REPLICATION; FATTY ACIDS; HEPATOCYTES; HUMANS; MICE; MICE, TRANSGENIC; OXIDATION-REDUCTION; PEROXISOME PROLIFERATORS; PYRIMIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SPECIES SPECIFICITY; TRANSCRIPTION FACTORS;

EID: 2542635631     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0322     Document Type: Article

References (33)

1. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999;20:649-88.
2. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-50.
3. Ashby J, Brady A, Elcombe CR, et al. Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum Exp Toxicol 1994;13(Suppl 2):S1-117.
4. Yeldandi AV, Rao MS, Reddy JK. Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis. Mutat Res 2000;448:159-77.
5. Rao MS, Reddy JK. Hepatocarcinogenesis of peroxisome proliferators. Ann N Y Acad Sci 1996;804:573-87.
6. Dietrich DR. Toxicological and pathological applications of proliferating cell nuclear antigen (PCNA), a novel endogenous marker for cell proliferation. Crit Rev Toxicol 1993;23:77-109.
7. Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci USA 1993;90:1112-6.
8. Wolowiec D, Deviller P, Simonin D, et al. Cdk1 is a marker of proliferation in human lymphoid cells. Int J Cancer 1995;61:381-8.
9. Miller RT, Glover SE, Stewart WS, Corton JC, Popp JA, Cattley RC. Effect on the expression of c-met, c-myc and PPAR-α in liver and liver tumors from rats chronically exposed to the hepatocarcinogenic peroxisome proliferator WY-14,643. Carcinogenesis 1996;17:1337-41.
10. Mitchell FE, Price SC, Hinton RH, Grasso P, Bridges JW. Time and dose-response study of the effects on rats of the plasticizer di(2-ethylhexyl) phthalate. Toxicol Appl Pharmacol 1985;81:371-92.
11. Lee SS, Pineau T, Drago J, et al. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 1995;15:3012-22.
12. Peters JM, Cattley RC, Gonzalez FJ. Role of PPAR α in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 1997;18:2029-33.
13. Bell AR, Savory R, Horley NJ, et al. Molecular basis of non-responsiveness to peroxisome proliferators: the guinea-pig PPARα is functional and mediates peroxisome proliferator-induced hypolipidaemia. Biochem J 1998;332(Pt 3):689-93.
14. Sher T, Yi HF, McBride OW, Gonzalez FJ. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 1993;32:5598-604.
15. Ljung B, Bamberg K, Dahllof B, et al. AZ 242, a novel PPARα/ γ agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J Lipid Res 2002;43:1855-63.
16. Palmer CN, Hsu MH, Griffin KJ, Raucy JL, Johnson EF. Peroxisome proliferator activated receptor-α expression in human liver. Mol Pharmacol 1998;53:14-22.
17. Gervois P, Torra IP, Chinetti G, et al. A truncated human peroxisome proliferator-activated receptor α splice variant with dominant negative activity. Mol Endocrinol 1999;13:1535-49.
18. Hsu MH, Savas U, Griffin KJ, Johnson EF. Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor α in HepG2 cells. J Biol Chem 2001;276:27950-8.
19. Lawrence JW, Li Y, Chen S, et al. Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) α. PPAR α fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression. J Biol Chem 2001;276:31521-7.
20. Yu S, Cao WQ, Kashireddy P, et al. Human peroxisome proliferator-activated receptor α (PPARα) supports the induction of peroxisome proliferation in PPARα-deficient mouse liver. J Biol Chem 2001;276:42485-91.
21. Chung JH, Bell AC, Felsenfeld G. Characterization of the chicken β-globin insulator. Proc Natl Acad Sci USA 1997;94:575-80.
22. Kistner A, Gossen M, Zimmermann F, et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci USA 1996;93:10933-8.
23. Akiyama TE, Ward JM, Gonzalez FJ. Regulation of the liver fatty acid-binding protein gene by hepatocyte nuclear factor 1α (HNF1α). Alterations in fatty acid homeostasis in HNF1α-deficient mice. J Biol Chem 2000;275:27117-22.
24. Aoyama T, Peters JM, Iritani N, et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα). J Biol Chem 1998;273:5678-84.
25. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992;89:5547-51.
26. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995;268:1766-9.
27. Peters JM, Hennuyer N, Staels B, et al. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice. J Biol Chem 1997;272: 27307-12.
28. Sauerberg P, Bury PS, Mogensen JP, et al. Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo. J Med Chem 2003;46:4883-94.
29. Peters JM, Aoyama T, Cattley RC, Nobumitsu U, Hashimoto T, Gonzalez FJ. Role of peroxisome proliferator-activated receptor α in altered cell cycle regulation in mouse liver. Carcinogenesis 1998;19:1989-94.
30. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
31. Childs M, Girardot G. [Evaluation of acquired data on long-term risk of hypolipidemic treatments]. Arch Mal Coeur Vaiss 1992;85:129-33.
32. Huttunen JK, Heinonen OP, Manninen V, et al. The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J Intern Med 1994;235:31-9.
33. Brown PJ, Stuart LW, Hurley KP, et al. Identification of a subtype selective human PPARα agonist through parallel-array synthesis. Bioorg Med Chem Lett 2001;11: 1225-7.